Taxonomy: Bacteria; Firmicutes; Bacilli; Bacillales; Staphylococcaceae;

Staphylococcus

Staphylococcus search

Read about Staphylococcus:

Hide info

Staphylococcus aureus

I. Organism Information

A. Taxonomy Information

1. Species

a. Staphylococcus aureus

i. Taxonomy ID: 1280

ii. Description:

Staphylococcus aureus is a Gram-positive pathogen that causes a wide range of diseases, and is becoming increasingly resistant to antibiotics (1). These resistant bacteria are called methicillin-resistant Staphylococcus aureus, or MRSA. S. aureus is responsible for a variety of ailments, including carbuncles, food poisoning, wound and medical device-related infections, bacteremia, necrotizing pneumonia, and endocarditis (2). S. aureus forms a fairly large yellow colony on rich medium and is hemolytic on blood agar. Staphylococci are facultative anaerobes that ferment glucose to lactate. The bacteria are catalase-positive and oxidase-negative. S. aureus can grow at a temperature range of 15 to 45 degrees and at NaCl concentrations as high as 15 percent. Almost all strains of S. aureus produce the enzyme coagulase. S. aureus should always be considered a potential pathogen (3).

To contribute more information, please contact help@nmpdr.org

iii. Variants

Staphylococcus aureus subsp. aureus
Taxonomy ID: 46170

Staphylococcus aureus subsp. aureus COL
Taxonomy ID: 93062
Parent: Staphylococcus aureus subsp. aureus

Staphylococcus aureus subsp. aureus MRSA252
Taxonomy ID: 282458
Parent: Staphylococcus aureus subsp. aureus

Staphylococcus aureus subsp. aureus MSSA476
Taxonomy ID: 282459
Parent: Staphylococcus aureus subsp. aureus

Staphylococcus aureus subsp. aureus MW2
Taxonomy ID: 196620

Parent: Staphylococcus aureus subsp. aureus

Staphylococcus aureus subsp. aureus Mu50
Taxonomy ID: 158878
Parent: Staphylococcus aureus subsp. aureus

Staphylococcus aureus subsp. aureus N315
Taxonomy ID: 158879
Parent: Staphylococcus aureus subsp. aureus

B. Lifecycle and Morphology

1. (To contribute to this description of the infection cycle, please contact help@nmpdr.org)

a. Shape:

Cocci 0.5-1.0 μm in diameter. Cells occur singly or in pairs. Division is in two planes, giving rise to clusters. Colonies are smooth, raised, glistening, circular, entire and translucent. Single colonies may obtain a size of 6-8 mm in diameter (4).

b. Picture:

SEM of Staphylococcus aureus
SEM of numerous clumps of methicillin-resistant Staphylococcus aureus bacteria, commonly referred to by the acronym, MRSA (magnified 9560x), by Janice Carr, CDC

C. Genome Summary

1. Genome of Staphylococcus aureus subsp. aureus COL

a. Chromosome

i. Genbank Accession Number: NC_002951
ii. Size: 2,809,422 bp
iii. S. aureus COL is an early methicillin-resistant isolate (5).

b. Plasmid pT181

i. Genbank Accession Number: NC_006629
ii. Size: 4,440 bp



II. References

1.  Sanger Institute

2.  Holden MT, Feil EJ, Lindsay JA, Peacock SJ, Day NP, Enright MC, Foster TJ, Moore CE, Hurst L, Atkin R, Barron A, Bason N, Bentley SD, Chillingworth C, Chillingworth T, Churcher C, Clark L, Corton C, Cronin A, Doggett J, Dowd L, Feltwell T, Hance Z, Harris B, Hauser H, Holroyd S, Jagels K, James KD, Lennard N, Line A, Mayes R, Moule S, Mungall K, Ormond D, Quail MA, Rabbinowitsch E, Rutherford K, Sanders M, Sharp S, Simmonds M, Stevens K, Whitehead S, Barrell BG, Spratt BG, Parkhill J. (2004) Complete genomes of two clinical Staphylococcus aureus strains: evidence for the rapid evolution of virulence and drug resistance. Proc. Natl. Acad. Sci. USA. 101: 9786-91.

3.   http://textbookofbacteriology.net/staph.html


4.   Bergey's Manual of Determinative Bacteriology, 9th edition. John G. Holt, Noel R. Krieg, Peter H.A. Sneath, James T. Staley, and Stanley T. Williams, editors. Baltimore: Williams and Wilkins, 1994, pp. 518.

5.   Gill SR, Fouts DE, Archer GL, Mongodin EF, Deboy RT, Ravel J, Paulsen IT, Kolonay JF, Brinkac L, Beanan M, Dodson RJ, Daugherty SC, Madupu R, Angiuoli SV, Durkin AS, Haft DH, Vamathevan J, Khouri H, Utterback T, Lee C, Dimitrov G, Jiang L, Qin H, Weidman J, Tran K, Kang K, Hance IR, Nelson KE, and Fraser CM. (2005) Insights on evolution of virulence and resistance from the complete genome analysis of an early methicillin-resistant Staphylococcus aureus strain and a biofilm-producing methicillin-resistant Staphylococcus epidermidis strain. J. Bacteriol. 187: 2426-2438.

Hide info

Hide info

Staphylococcus - Google News

©2016 Google

Staphylococcus Aureus Infections Pipeline Review 2016 Industry Analysis, Market Size and Analysis 2020 - Medgadget.com (blog)


Staphylococcus Aureus Infections Pipeline Review 2016 Industry Analysis, Market Size and Analysis 2020
Medgadget.com (blog)
Staphylococcus Aureus Infections report also includes an review of trial numbers and also their ( Staphylococcus Aureus Infections ) average enrollment in uppermost countries which are conducted globaly on Staphylococcus Aureus Infections scenario.

and more »

Enzymatic degradation of in vitro Staphylococcus aureus biofilms supplemented with human plasma - Dove Medical Press


Enzymatic degradation of in vitro Staphylococcus aureus biofilms supplemented with human plasma
Dove Medical Press
Some of the enzymes utilized for debridement have been tested against bacterial pathogens, but the effectiveness of these agents in dispersing clinically relevant biofilms has not been fully characterized. Here, we developed an in vitro Staphylococcus ...

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections Pipeline Review, Industry Analysis, Market Size and ... - Medgadget.com (blog)


Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections Pipeline Review, Industry Analysis, Market Size and ...
Medgadget.com (blog)
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections Global 2016 Clinical Trials Review, H2 provides an detailed overview of Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections scenario. Report includes top line data relating ...

Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Market Report 2016-2020 - Analysis, Technologies ... - Business Wire (press release)


Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Market Report 2016-2020 - Analysis, Technologies ...
Business Wire (press release)
This Methicillin-resistant Staphylococcus aureus (MRSA) - Market Insights, Epidemiology and Market Forecast-2020 report provides an overview of the disease and global market trends for the seven major markets i.e.: United States, EU5 (France, Germany, ...

and more »

Methicillin-Resistant Staphylococcal Periprosthetic Joint Infections Can Be Effectively Controlled by Systemic and ... - Medscape


Methicillin-Resistant Staphylococcal Periprosthetic Joint Infections Can Be Effectively Controlled by Systemic and ...
Medscape
Background: Methicillin-resistant Staphylococcus remains a serious problem in the treatment of periprosthetic joint infection (PJI). Higher failure rates were reported when vancomycin was used in 2-stage exchange arthroplasty. Therefore a better ...

PharmaPoint Report: Methicillin-Resistant Staphylococcus Aureus (MRSA) - Global Drug Forecast and Analysis to ... - Business Wire (press release)


PharmaPoint Report: Methicillin-Resistant Staphylococcus Aureus (MRSA) - Global Drug Forecast and Analysis to ...
Business Wire (press release)
Today, the MRSA market is highly competitive, as physicians have a myriad of antimicrobial agents at their disposal that are approved to treat these severe and often life-threatening infections. There are currently over 10 marketed antibiotics that ...

and more »

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Pipeline Review, Market Growth, Segment, Trends and ... - Medgadget.com (blog)


Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Pipeline Review, Market Growth, Segment, Trends and ...
Medgadget.com (blog)
market-research-store138 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Pipeline Review, H2 2016 , provides an overview of the Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections 's therapeutic pipeline. This report provides ...

and more »

Staphylococcus Albus Global (Us, Eu, Japan & China) Supply And Consumption Industry 2016 To 2021 Market ... - NewsMaker (press release)


Staphylococcus Albus Global (Us, Eu, Japan & China) Supply And Consumption Industry 2016 To 2021 Market ...
NewsMaker (press release)
The 'Global And Chinese Staphylococcus Albus Industry, 2011-2021 Market Research Report' Is A Professional And In-Depth Study On The Current State Of The Global Staphylococcus Albus Industry With A Focus On The Chinese Market. The Report ...

and more »

Hospital Visitors and Isolation Precautions: Clearing Up the Confusion - Medscape


Medscape

Hospital Visitors and Isolation Precautions: Clearing Up the Confusion
Medscape
The recommendations address endemic situations for which contact isolation measures are often used by healthcare workers, such as methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE). In outbreaks or times of ...

and more »

Septic Arthritis: Household Dangers That Can Cause Infection - Newsmax


Septic Arthritis: Household Dangers That Can Cause Infection
Newsmax
The bacteria strains that cause septic arthritis, such as staphylococcus, streptococcus, and certain types of influenza, are commonly found in most homes. Those with weakened immune systems like infants, the elderly, and people with other types of ...

and more »

Hide info

Staphylococcus genome sequence annotation status: click numbers to browse lists of genes or subsystems

Strain annotated in NMPDR Phenotype Genome size, bp Protein Encoding Genes (PEGs) Sort Named genes in subsystems Named genes not in subsystems Hypothetical genes in subsystems Hypothetical genes not in subsystems Subsystems RNAs
Staphylococcus aureus RF122 Bovine mastitis 2,742,531 2,523 1213(45.4%) 731(27.4%) 113(4.2%) 615(23.0%) 316 110
Staphylococcus aureus subsp. aureus COL methicillin resistant, hospital acquired (MRSA) 2,813,862 2,622 1247(44.8%) 718(25.8%) 98(3.5%) 722(25.9%) 330 108
Staphylococcus aureus subsp. aureus JH1 vancomycin susceptible, hospital acquired (MRSA) 2,879,577 2,685 1194(43.4%) 779(28.3%) 110(4.0%) 666(24.2%) 314 172
Staphylococcus aureus subsp. aureus JH9 vancomycin nonsusceptible, isogenic to JH1, hospital acquired (MRSA, VISA) 2,862,918 2,675 1202(43.9%) 773(28.2%) 108(3.9%) 657(24.0%) 316 165
Staphylococcus aureus subsp. aureus MRSA252 methicillin resistant, hospital acquired (MRSA) 2,902,619 2,663 1254(45.7%) 756(27.5%) 77(2.8%) 659(24.0%) 338 110
Staphylococcus aureus subsp. aureus MSSA476 methicillin susceptible, community acquired 2,820,454 2,609 1231(45.1%) 763(28.0%) 82(3.0%) 652(23.9%) 335 157
Staphylococcus aureus subsp. aureus MW2 methicillin resistant, community acquired (CA-MRSA) 2,820,462 2,644 1202(43.7%) 790(28.7%) 92(3.3%) 669(24.3%) 337 53
Staphylococcus aureus subsp. aureus Mu3   2,880,168 2,495 1094(43.7%) 768(30.7%) 90(3.6%) 549(22.0%) 296 108
Staphylococcus aureus subsp. aureus Mu50 methicillin and vancomycin resistant, hospital acquired (MRSA, VRSA) 2,903,147 2,771 1293(44.0%) 818(27.9%) 142(4.8%) 683(23.3%) 337 108
Staphylococcus aureus subsp. aureus N315 methicillin resistant, hospital acquired (MRSA) 2,839,469 2,648 1279(45.3%) 814(28.9%) 90(3.2%) 638(22.6%) 340 110
Staphylococcus aureus subsp. aureus NCTC 8325 lab strain 2,821,361 2,895 1222(39.9%) 832(27.1%) 110(3.6%) 901(29.4%) 320 109
Staphylococcus aureus subsp. aureus USA300 methicillin resistant, community acquired (CA-MRSA) 2,917,469 2,607 1223(44.1%) 833(30.1%) 86(3.1%) 629(22.7%) 316 105
Staphylococcus aureus subsp. aureus str. Newman   2,878,897 2,523 1077(42.6%) 782(30.9%) 71(2.8%) 599(23.7%) 293 109
Staphylococcus epidermidis ATCC 12228   2,564,615 2,472 1147(44.7%) 723(28.2%) 47(1.8%) 647(25.2%) 325 118
Staphylococcus epidermidis RP62A   2,643,840 2,529 1122(42.7%) 678(25.8%) 45(1.7%) 780(29.7%) 316 120
Staphylococcus haemolyticus JCSC1435   2,697,861 2,694 1164(41.8%) 773(27.7%) 53(1.9%) 796(28.6%) 323 111
Staphylococcus saprophyticus subsp. saprophyticus ATCC 15305   2,577,899 2,517 1140(43.7%) 765(29.3%) 42(1.6%) 662(25.4%) 327 122
Topic revision: r6 - 23 Aug 2008 - 11:08:12 - Bruce Parrello
 
Notice to NMPDR Users - The NMPDR BRC contract has ended and bacterial data from NMPDR has been transferred to PATRIC (http://www.patricbrc.org), a new consolidated BRC for all NIAID category A-C priority pathogenic bacteria. NMPDR was a collaboration among researchers from the Computation Institute of the University of Chicago, the Fellowship for Interpretation of Genomes (FIG), Argonne National Laboratory, and the National Center for Supercomputing Applications (NCSA) at the University of Illinois. NMPDR is funded by the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract HHSN266200400042C. Banner images are copyright © Dennis Kunkel.